Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies.

ABSTRACT: Immune checkpoint inhibition (ICI) therapies have reshaped the therapeutic landscape in lung cancer management, providing first-time improvements in patient response, prognosis, and overall survival. Despite their clinical effectiveness, variability in treatment responsiveness, as well as drug resistance, have led to a compelling need for predictive biomarkers facilitating the individualized selection of the most efficient therapeutic approach. Significant progress has been made in the identification of such biomarkers, with tumor mutation burden (ΤΜΒ) appearing as the leading and most promising predictive biomarker for the efficacy of ICIs in non-small cell lung cancer (NSCLC) among other tumors. Anti-PD-1/PD-L1 and anti-CTLA-4 antibodies have been extensively studied and clinically utili

SUBMITTER: Vryza P 

PROVIDER: S-EPMC10542015 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature